Related Experiment Video
Updated: Jul 7, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antiarrhythmic drug therapy during pregnancy
Annals of Internal Medicine
|April 1, 1983
Summary
Pregnancy heightens cardiac workload, increasing risks for pregnant women with heart disease and arrhythmias. Careful antiarrhythmic drug selection and dosage are crucial to protect both mother and fetus.
Area of Science:
- Cardiology
- Maternal-Fetal Medicine
- Pharmacology
Background:
- Pregnancy significantly increases cardiac demands due to elevated blood volume and cardiac output.
- Cardiac arrhythmias in pregnant women with pre-existing heart disease can lead to severe hemodynamic compromise, endangering both mother and fetus.
- Advances in medical therapy allow more women with cardiac conditions to reach reproductive age, necessitating antiarrhythmic medication during pregnancy.
Purpose of the Study:
- To review the principles and considerations for managing arrhythmias in pregnant patients.
- To highlight the limited data on antiarrhythmic drug effects on the human fetus.
- To emphasize the need for careful drug selection and dosage adjustments during pregnancy.
Main Methods:
- Literature review of existing studies and clinical guidelines on antiarrhythmic drug use in pregnancy.
- Analysis of hemodynamic changes during pregnancy and their impact on cardiac function.
- Discussion of potential risks and benefits of antiarrhythmic agents for mother and fetus.
Main Results:
- The fundamental approach to treating arrhythmias in pregnant patients mirrors that in non-pregnant individuals.
- Specific antiarrhythmic agents require careful consideration due to potential adverse effects on fetal development.
- Dosage adjustments may be necessary to account for physiological changes during pregnancy.
Conclusions:
- Managing arrhythmias during pregnancy requires a balance between maternal and fetal well-being.
- Further research is needed to fully understand the safety and efficacy of antiarrhythmic drugs in pregnant populations.
- Individualized treatment plans are essential, prioritizing maternal and fetal safety.
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...